Physician profile
Daniel B Hall
NPI 1508369224
$1,210.96
in general payments reported to CMS, 2019-2025
19 companies · $839 in 2025
The $839 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $87.03 · 2024: $285 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,123.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $200.59 | 2024-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $156.89 | 2024-2025 | Airsupra, Farxiga |
| Dexcom, INC. | $119.30 | 2025 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $102.70 | 2024-2025 | Licart, Tirosint, Flector |
| Boston Scientific Corporation | $87.03 | 2021 | |
| Lilly USA, LLC | $83.35 | 2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $82.58 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $69.67 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Renalytix Ai, INC. | $49.59 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Sumitomo Pharma America, INC. | $44.78 | 2025 | Gemtesa |
| Shield Therapeutics INC | $43.15 | 2024-2025 | |
| Pfizer INC. | $35.53 | 2024-2025 | |
| Abbvie INC. | $29.33 | 2025 | |
| Sanofi-Aventis U.S. LLC | $20.65 | 2025 | |
| Azurity Pharmaceuticals, INC. | $19.12 | 2024 | Horizant |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $18.63 | 2025 | Aptima, Thinprep 2000 Processor |
| Takeda Pharmaceuticals U.S.A., INC. | $17.95 | 2025 | Trintellix |
| Amgen INC. | $15.63 | 2024 | Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $14.49 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.